A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

  • STATUS
    Not Recruiting
  • End date
    Sep 22, 2022
  • participants needed
    740
  • sponsor
    AbbVie
Updated on 26 January 2021
maintenance therapy
metastasis
platinum-based chemotherapy
extensive stage small cell lung cancer
rovalpituzumab tesirine

Summary

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.

Only China and South Korea will remain open to recruiting.

Details
Condition Small Cell Lung Cancer
Treatment Dexamethasone, Rovalpituzumab tesirine, Placebo for rovalpituzumab tesirine, Placebo for dexamethasone
Clinical Study IdentifierNCT03033511
SponsorAbbVie
Last Modified on26 January 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note